Project Grant R21HL184337
- The National Heart, Lung, and Blood Institute (NHLBI) at the Department of Health and Human Services awarded The Leland Stanford Junior University $755,271 on August 25, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop, validate, and clinically evaluate a magnetic resonance imaging method for assessing blood flow hemodynamics in pediatric and young adult congenital heart disease patients. The project will augment 4D-flow MRI capabilities to enable direct...
- The National Heart, Lung, and Blood Institute awarded The Leland Stanford Junior University $770,000 on April 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to fund research unraveling endothelial-cardiomyocyte crosstalk in cardiomyopathy using an integrated multimodal approach. The research examines molecular mechanisms by which endothelial dysfunction contributes to cardiac dysfunction in cardiomyopathy, focusing on cell-to-cell signaling between endothelial cells...
- The National Heart, Lung, and Blood Institute awarded The Washington University $803,772 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of the mitochondrial calcium uniporter in platelet function and thrombosis. The research addresses ischemic stroke prevention through basic and translational science. Approximately 700,000 people in the United States experience ischemic stroke annually, and current acute treatments restrict...
- The National Institutes of Health National Heart Lung and Blood Institute awarded The General Hospital Corporation (Massachusetts General Hospital) $186,840 under CFDA 93.837 Cardiovascular Diseases Research on July 3, 2026, for advanced analysis of high-resolution cardiac diffusion tensor imaging (DTI). The funded work develops and applies DTI phenomapping, a voxel-level quantitative analysis approach for cardiac magnetic resonance imaging that resolves distinct microstructural patterns in...
- The National Heart, Lung, and Blood Institute awarded The Leland Stanford Junior University $767,249 on June 22, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and validate computational models for designing organ-scale vasculature in biomanufactured cardiac tissues. The project addresses the need for patient-specific engineered tissues to repair complex congenital heart defects, particularly large ventricular septal defects where current surgical approaches...
- The National Heart, Lung, and Blood Institute awarded The Regents of the University of California, San Francisco $246,000 on August 14, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to analyze clinician-level variation in chest pain admission practices and its impact on downstream patient outcomes. The research will evaluate how emergency department clinicians' admitting tendencies for chest pain patients without acute coronary syndrome evidence affect subsequent testing...
- The National Heart, Lung, and Blood Institute awarded the University of Virginia $760,465 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop deep learning methods that advance cardiac magnetic resonance strain imaging for personalized cardiac resynchronization therapy treatment planning. The award funds development of deep strain networks to rapidly and accurately predict myocardial displacements from cardiac magnetic resonance imaging, addressing...
- The National Heart, Lung, and Blood Institute awarded the University of Virginia $802,973 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop rapid point-of-care molecular imaging of immune activation in acute coronary syndrome and acute myocarditis using targeted microbubble contrast agents. The project applies myocardial contrast echocardiography with phosphatidylserine-incorporating lipid microbubbles (MB-PS) to detect inflammatory activation from...
- The National Heart, Lung, and Blood Institute awarded Vanderbilt University Medical Center $174,621 on August 17, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop cardiac magnetic resonance imaging (CMR) techniques for monitoring congenital heart disease using ultra-low field (ULF) MRI systems. The recipient will adapt CMR to an inexpensive, unshielded, open-geometry ULF MRI system and apply machine learning techniques to mitigate hardware limitations and...
- The National Heart Lung and Blood Institute awarded Case Western Reserve University $1,573,126 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop an artificial intelligence-based decision-support tool that identifies patients at risk of myocardial ischemia using low-cost or no-cost screening data. The tool will analyze CT calcium scores, electrocardiogram data, and clinical risk factors to serve as a gatekeeper strategy for determining which patients...
The National Heart, Lung, and Blood Institute awarded The Regents of the University of California, San Francisco $902,000 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop an abbreviated cardiovascular magnetic resonance imaging solution for time-efficient, cost-effective etiology diagnosis of acute ischemic stroke. The project develops a 10-minute abbreviated cardiovascular MRI protocol designed to identify the underlying cause of acute ischemic stroke within a single examination. Standard stroke etiology workup fails to identify a definitive cause in 20 to 30 percent of ischemic strokes, resulting in a diagnosis of cryptogenic stroke, and misclassification rates range from 14 to 55 percent. The abbreviated solution addresses the clinical need to expedite multi-station etiology evaluation, reduce diagnostic timeline delays, and decrease burden on patients and the healthcare system by consolidating imaging workup that currently requires multiple modalities and extended evaluation periods. Work is performed in San Francisco, California, with a period of performance from August 1, 2026, through July 31, 2028. The award is a Project Grant, an assistance type that supports a discrete, circumscribed research project.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 8/20/26 | ||
| Not listed | $451.0k | 8/4/26 |